ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Savara Granted Breakthrough Therapy Designation for Molgradex americanpharmaceuticalreview
January 07, 2020Savara announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of aPAP. -
IMPALA Phase 3 Study of Molgradex Does Not Meet Primary Endpoint americanpharmaceuticalreview
June 14, 2019Savara announced top line data from IMPALA, a pivotal Phase 3 clinical study evaluating Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of aPAP ...
Pharma Sources Insight January 2025
